Tego Science KRX:191420KOSDAQ
테고사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, Tego Science reported revenue of ₩2.0bn, up 21.9% year on year, and an operating loss of ₩1.2bn. Tego Science (테고사이언스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Tego Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.0bn | +21.9% | −₩1.2bn margin −58.5% | −₩4.9bn |
| Q1 2026 | ₩1.2bn | -8.7% | −₩1.9bn margin −155.8% | −₩2.0bn |
| Q4 2025 derived | ₩1.4bn | -13.3% | −₩2.1bn margin −152.1% | −₩5.0bn |
| Q3 2025 | ₩1.6bn | -18.3% | −₩955m margin −59.0% | −₩981m |
| Q2 2025 | ₩1.6bn | -14.8% | −₩463m margin −28.6% | −₩338m |
| Q1 2025 | ₩1.3bn | +3.0% | −₩888m margin −67.6% | −₩658m |
| Q4 2024 derived | ₩1.6bn | -9.5% | −₩1.1bn margin −68.3% | −₩1.3bn |
| Q3 2024 | ₩2.0bn | -2.3% | −₩148m margin −7.5% | ₩370m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Tego Science top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.